ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2020
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.
Open access · hybridAbstract read
In one paragraph
Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years.Frontiers in oncology · 2024Pooled it
- Autologous-allogeneicHaematologica · 2024Trial
- A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial.Transplantation and cellular therapy · 2023Trial
- Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT.Bone marrow transplantation · 2025Article
- Tandem autologous hematopoietic stem cell transplantation in multiple myeloma: A historical perspective and current challenges.Annals of hematology · 2025Review
- Is there still a place for autologous salvage transplantation in relapsed/refractory multiple myeloma in the era of novel therapies?Annals of hematology · 2025Article
- Historical Perspective of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma.Acta haematologica · 2025Review
- Allogeneic stem cell transplantation in multiple myeloma: is there still a place?Frontiers in oncology · 2024Review
- Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective.Transplantation and cellular therapy · 2022Review
- Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma.Oncology and therapy · 2022Review
- The Insider: Impact of the Gut Microbiota on Cancer Immunity and Response to Therapies in Multiple Myeloma.Frontiers in immunology · 2022Review
- Review
- Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.Journal of clinical medicine · 2021Review
- Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity.Cancers · 2021Review
- The Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma: A Systematic Review of the Literature.Cureus · 2021Review
- Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.HemaSphere · 2021Article
- Prognostic Factors for Postrelapse Survival after ex Vivo CD34Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Article
- Allogeneic Hematopoietic Transplantation for Multiple Myeloma in the New Drugs Era: A Platform to Cure.Journal of clinical medicine · 2020Review
- Allogeneic Transplantation in Multiple Myeloma-Does It Still Have a Place?Journal of clinical medicine · 2020Review
- Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 13 institutions in 1 country.
Sergio GiraltAdult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: GiraltS@mskcc.org.
Luciano J CostaDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
David MaloneyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Amrita KrishnanDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Mingwei FeiCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Joseph H AntinDivision of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Claudio BrunsteinDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Nancy GellerNational Institutes of Health-National Heart, Lung, and Blood Institute Government Agency Partners, Bethesda, Maryland.
Stacey GoodmanVA Tennessee Valley HCS HSCT Program Nashville, Vanderbilt University Medical Center, Nashville, Tennessee.
Parameswaran HariCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Brent LoganCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin.
Robert LowskyDivision of Blood and Marrow Transplantation, Stanford University Medical, Stanford, California.
Muzaffar H QazilbashDepartment of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, Texas.
Firoozeh SahebiDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
George SomloDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Scott RowleyJohn Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey; Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC.
Dan T VoglAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
David H VesoleJohn Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey.
Marcelo PasquiniCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Edward StadtmauerAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
Medical College of Wisconsin · USCity of Hope · USHackensack University Medical Center · USUniversity of Pennsylvania · USDana-Farber Cancer Institute · USFred Hutch Cancer Center · USMemorial Sloan Kettering Cancer Center · USNational Institutes of Health · USStanford University · USThe University of Texas MD Anderson Cancer Center · USUniversity of Alabama at Birmingham · USUniversity of Minnesota · USVanderbilt University Medical Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MSWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1MData Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MBlood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4MPB vs. BMU01HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2001 to 2010
$63.3MCity of Hope Core Clinical Center for the Blood and Marrow Transplant Clinical Trials NetworkUG1HL069278 · NHLBI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI RYOTARO NAKAMURA · 2017 to 2026
$2.2MBMT CTN Core- University of Pennsylvania Abramson Cancer CenterUG1HL069286 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Edward A Stadtmauer · 2017 to 2026
$2.0MReduced intensity vs myeloablative conditioning for old*U01HL069334 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHAMPLIN, RICHARD E. · 2002 to 2010
$1.8MMSKCC BMT CTN Renewal U10HL069315 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI GIRALT, SERGIO A · 2011 to 2016
$1.1MNCI NIH HHS P30 CA008748NCI NIH HHS U10 CA180888NCI NIH HHS U24 CA076518NHLBI NIH HHS U01 HL069294NHLBI NIH HHS U01 HL069334NHLBI NIH HHS U10 HL069315NHLBI NIH HHS U24 HL138660NHLBI NIH HHS UG1 HL069278NHLBI NIH HHS UG1 HL069286
Abstract
Allogeneic hematopoietic cell transplant (HCT) may improve long-term multiple myeloma (MM) control through the graft-versus-myeloma effect. The Blood and Marrow Transplant Clinical Trials Network 0102 trial was a biologic assignment trial comparing tandem autologous transplant (auto-auto) versus autologous followed by reduced-intensity allogeneic (auto-allo) transplant in patients with newly diagnosed MM with standard-risk (n = 625) or high-risk (n = 85; β
Indexed as
Hematopoietic Stem Cell TransplantationMultiple MyelomaBone MarrowDisease-Free SurvivalFollow-Up StudiesHumansNeoplasm Recurrence, LocalTransplantation, AutologousTransplantation, HomologousAllogeneicAutologousMultiple myelomaTransplantation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.